IN VITRO ANALYTICAL EVALUATION OF NITROSAMINE – A CARCINOGENIC IMPURITIES IN OLMESARTAN MEDOXIMIL BY GC MS/MS METHOD

  • NDVR SARADHI Department of Pharmacy, Santhiram College of Pharmacy, Nandyal, Andhra Pradesh, India.
  • K KALYAN KUMAR Department of Chemistry, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India.
  • M VENKATA REDDY Department of Pharmacy, Sree Dattha Institute of Pharmacy, Hyd. Ex Drug Controller, Hyderabad, Telangana, India.

Abstract

Objective: A simple and sensitive method development and validation for the simultaneous determination of the N-nitrosamine dimethylamine (NDMA) and N Nitrosamine diethylamine (NDEA) in Olmesartan medoxomil (OLM) API and formulations by a tandem mass spectrometer (GC-MS/MS).


Methods: Gas chromatography with a programmed oven temperature controller, Elite Wax (30 m × 0.25 mm × 0.5 μm) column, Helium as carrier gas and hyphenated to the tandem mass spectrometer powered with triple quadrupole mass analyzer, and photomultiplier tube detector. The method was validated as per the United States Food and Drug Administration (USFDA) guidelines.


Results: With the selected GC-MS/MS conditions, the NDMA and NDEA 0.08 μg/ml (80 ng/ml) and 0.16 μg/ml (160 ng/ml) injected and Rt. for NDMA 5.634 and NDEA 6.516 min, respectively. A linear/range lies in between 0.024 and 0.120 μg/ml and 0.048 and 0.240 μg/ml for NDMA and NDEA with r2 >0.99. The precision, accuracy, and system suitability are established as per USFDA and ICH guidelines, the sensitivity of NDMA limit of detection and limit of quantification 0.08, 0.024 and NDEA 0.16, 0.048.


Conclusion: Other nitrosamine impurities are not involved in the determination of NDMA and NDEA in the OLM using GC-MS/MS and the method is simple, sensitive, rapid, accurate, and precise.

Keywords: Nitrosamine Dimethylamine, Nitrosamine diethylamine, Carcinogenic impurities, Gas chromatography-mass spectrometry, Validation, Olmesartan Medoxomil

Author Biography

NDVR SARADHI, Department of Pharmacy, Santhiram College of Pharmacy, Nandyal, Andhra Pradesh, India.

PHARMACEUTICAL ANALYSIS

ASSOCIATE PROFESSOR

References

1. Chem P. Olmnesartan Medoxomil. Bethesda, Maryland: National Library of Medicine; 2015.
2. Available from: https://www.who.int/medicines/publications/ drugalerts/informationnote_nitrosamine-impurities/en.
3. Food and Drug Administration. USFDA Combined Headspace N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), and N-Nitrosodiisopropylamine (NDIPA) Impurity Assay by GC-MS/MS. United States: Food and Drug Administration; 2019. p. 1-7.
4. Keitel S. EDQM Director Training Sessions of European Pharmacopeia 5th Revision. France European Directorate for the Quality of Medicines and HealthCare; 2019. p. 1-14.
5. Food and Drug Administration. USFDA Combined Headspace N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), and N-Nitrosodiisopropylamine (NDIPA) Impurity Assay by GC-MS/MS. United States: Food and Drug Administration;2019 p 1-7.
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline. United States: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1994.
7. Mina SA, El-Maksoud AM, Mohammed HS. Study of the anti-hyperlipidemic effect of the combined administration of three natural extracts in a poloxamer-407 hyperlipidemic model and their lc-esi-ms/ ms2 and hplc profiling. Int J Pharm Pharm Sci 2020;12:29-35.
8. Sharma A, Kumar I, Rana K. RP-HPLC method development and validation for the combination of imiquimod and salicylic acid. Int J Pharm Pharm Sci 2020;12:41-8.
9. Maneka SL, Saravanakumar RT, Anjana CH. Development and validation of stability-indicating RP-UPLC method for the simultaneous estimation of tezacaftor and ivacaftor in formulations. Int J Pharm Pharm Sci 2020;12:63-70.
10. Vinzuda DU, Sailor GU, Sheth NR. RP-HPLC method for determination of valsartan in tablet dosage form. Int J ChemTech Res 2010;2:1461-7.
11. Shaik KM, Sarmah B, Wadekar GS, Kumar P. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques. Critical Rev Anal Chem 2020;20:1-9.
12. Taylor N, Fauset A, Harpin V et al. Analysis of NDMA and NDEA using the Agilent 7697A HS Sample, 8890/5977 GC/MS System. Application Note Pharma and Biopharma; 2020 p. 1-6.
13. Haller H, Ito S, Izzo JL Jr., Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in Type 2 diabetes. N Engl J Med 2011;364:907-17.
14. Hasan M, Al Masud A, Ahmed J. Development and validation of a reversed phase HPLC method for simultaneous estimation of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage form. Int J Pharm Sci Res 2010;1:80-4.
15. Health IH. Available from: https://www.ich.org/page/ quality-guidelines.
16. Imam SS, Ahad A, Aqil M, Sultana Y, Ali A. A validated RP-HPLC method for simultaneous determination of propranolol and valsartan in bulk drug and gel formulation. J Pharm Bioallied Sci 2013;51:61.
17. Jain PS, Patel MK, Gorle AP, Chaudhari AJ, Surana SJ. Stability-indicating method for simultaneous estimation of olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide by RP-HPLC in tablet dosage form. J Chromatogr Sci 2012;50:680-7.
18. Joshi DM. Nitrosamine Impurities-current Status and Expectations. India: Indian Pharmaceutical Alliance; 2005.
19. Kemble AY, Mahadik MV, Khatal LD, Dhaneshwar SR. Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besilate and olmesartan medoxomil in bulk drug and formulation. Anal Lett 2010;43:251-8.
20. Keitel DS. Nitrosamine Contamination of Sartans Actions Taken by the EDQM. In: The European Directorate for the Quality of Medicines and Health Care; 2019. p. 1-14.
21. Mhaske RA, Garole DJ, Mhaske AA, Sahasrabudhe S. RP-HPLC method for simultataneous determination of amlodipine besilate, valsartan, telmisartan, hydrochlorothiazide and chlorthalidone: Application to commercially available drug products. Int J Pharm Sci Res 2012;3:141.
22. Lim HH, Oh YS, Shin HS. Determination of N-Nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2020;2020:113460.
23. Sawale V, Dangre P, Dhabarde DI. Development and validation of RP-HPLC method for the simultaneous estimation of olmesartan medoxomil and chlorthalidone in tablet dosage form. Int J Pharm Pharm Sci 2015;7:266-9.
24. Chaitanyaprasad MK, Vidyasagar G, Rao KR, Ramanjeneyulu S. Development of RP-HPLC method for estimation of Olmesartan medoxomil in tablet dosage forms. Pharm Chem 2011;3:208-12.
25. Muralidharan S, Rajkumar JR. Sensitive estimation of olmesartan medoxomil tablets by RP-HPLC method. Int J Pharm Life Sci 2012;3:2149-52.
26. Parr MK, Joseph JF. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. J Pharm Biomed Anal 2019;164:536-49.
27. Patel PS, More HN, Pishwikar SA. RP-HPLC method for simultaneous estimation of amlodipine besilate and olmesartan medoxomil from tablet. Int J Pharm Sci 2011;3 Suppl 3:3-6.
28. Patel DD, Patel MM. Simultaneous estimation of metoprolol succinct and Olmesartan medoxomil in pharmaceutical dosage form by UV spectroscopy. Int J Res Pharm Biomed Sci 2012;3:935-9.
29. Rao MP, Srikanth M, Umamaheswari K. Simultaneous estimation of ramipril and olmesartan medoxomil by RP-HPLC method. Int J Pharm Chem Anal 2017;4:106-11.
30. Rudrapal M, Oduri MU, Samidala NR, Kiran BS, Junejo JA, Singh KD. Development and validation of RP-HPLC method for simultaneous estimation of olmesartan and hydrochlorothiazide in tablet dosage form. Orient J Chem 2015;31:921-6.
31. Sagirli O, Önal A, Toker SE, ?ensoy D. Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies. Chromatographia 2007;66:213-8.
32. Shah SK, Asnani AJ, Kawade DP, Dangre SC, Arora SK, Yende SR. Simultaneous quantitative analysis of olmesartan medoxomil and amlodipine besilate in plasma by high-performance liquid chromatography technique. J Young Pharm 2012;4:88-94.
33. Sharma R, Pancholi S. RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions. Acta Pharm 2010;60:13-24.
34. Shimadzu global analytical and measuring instruments Corporation Analysis of Nitrosamines in Sartan-Type Bulk Drug Substances. Korea: Shimazdu; 2019 p 1-4.
35. Margaret Maziarz, Paul rainville et al waters corporation Milford USA HPLC Method for Detection of NDMA in Valsartan Drug Substance. Wheeling, Illinois: Sielc Technologies;2019 p 1-5.
36. Ghanty S, Das R, Maity S, Sen KK. RP-HPLC method for estimation of valsartan in solid oral dosage forms. J Pharm Sci Tech 2014;3:88-91.
37. Bhat PP, Balamuralidhara V, Gowrav MP, Venkatesh MP. Nitrosamines in drug substance and drug product-a regulatory challenge. Int J Res Pharm Sci 2020;11:2123-30.
38. Vidyadhara S, Sasidhar RL, Rao BV, Tejaswi K, Reshma M. Method development and validation for simultaneous estimation of olmesartan medoxomil and hydrochlorothiazide by RP-HPLC. Orient J Chem 2014;30:195-201.
Statistics
93 Views | 115 Downloads
Citations
How to Cite
SARADHI, N., K. K. KUMAR, and M. V. REDDY. “IN VITRO ANALYTICAL EVALUATION OF NITROSAMINE – A CARCINOGENIC IMPURITIES IN OLMESARTAN MEDOXIMIL BY GC MS/MS METHOD”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 12, Dec. 2020, pp. 89-94, doi:10.22159/ajpcr.2020.v13i12.39052.
Section
Original Article(s)